News for Harvard Bioscience, Inc. (HBIO)

**media[643793]**

In recent developments, the stock of Harvard Bioscience (HBIO) has been the subject of an updated analyst rating. As of May 13, 2025, analyst Bruce Jackson from

Revenue: $21.8 million, down from $24.5 million in Q1 2024.Gross Margin: 56%, compared to 60.3% in Q1 2024.Operating Loss: $49.7 million, primarily due to a $4

May 12, 2025 / 12:00PM GMTOperator Good day and welcome to the first quarter 2025 Harvard Bioscience Inc earnings conference call. (Operator Instructions)Please

Key Highlights: Harvard Bioscience (HBIO) anticipates Q2 revenue between $18 million and $20 million amidst macroeconomic challenges. The stock shows a r

Discover key insights from Harvard Bioscience's Q1 2025 earnings call: new product launches, market challenges, revenue outlook, and strategies for growth.

The following slide deck was published by Harvard Bioscience, Inc.

Harvard Bioscience (HBIO) disclosed a drop in first-quarter revenue, totaling $21.8 million compared to $24.5 million in the same period the previous year. The

Harvard Bioscience Inc (HBIO) is set to release its Q1 2025 earnings on May 12, 2025. The consensus estimate for Q1 2025 revenue is $19.20 million, and the earn

Harvard Bioscience (HBIO) to announce Q1 2025 earnings on May 12, 2025. The earnings conference call is scheduled for 8:00 AM Eastern Time on the same d

**media[592060]**

Revenue: $24.6 million in Q4 2024, down 13% year-over-year, up 12% sequentially from Q3.Gross Margin: $14 million or 57% of revenue in Q4 2024, compared to 58%

Mar 12, 2025 / 12:00PM GMTOperator Good day and welcome to the fourth quarter of 2024 Harvard Bioscience earnings conference call. (Operator instructions) This

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. ( HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, an

**media[564855]**

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Results Conference Call March 12, 2025 8:00 AM ETCompany ParticipantsKathryn Flynn - Corporate ControllerJim...

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. ( HBIO) (the ”œCompany”) today announced financial results for the fourth qua

**media[564238]**

Advanced platforms for CROs, pharmaceutical and biotech companies seeking to enhance productivity HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvar